- Home
- BIII vs SLN Comparison
BIII vs SLN Comparison
Compare BIII & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BIII | SLN |
|---|---|---|
| Founded | 2025 | 1994 |
| Country | Hong Kong | United Kingdom |
| Employees | N/A | 116 |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.9M | 236.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BIII | SLN |
|---|---|---|
| Price | $9.92 | $5.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $39.67 |
| AVG Volume (30 Days) | ★ 161.1K | 158.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.91 | $1.97 |
| 52 Week High | $9.97 | $7.78 |
Technical Indicators
Market Signals| Indicator | BIII | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 39.29 | 55.73 |
| Support Level | N/A | $5.07 |
| Resistance Level | $9.94 | $6.04 |
| Average True Range (ATR) | 0.01 | 0.40 |
| MACD | -0.00 | 0.13 |
| Stochastic Oscillator | 16.67 | 82.14 |
Price Performance
Historical ComparisonAbout BIII Black Spade Acquisition III Co Class A Ordinary Shares
Black Spade Acquisition III Co is a blank check company.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.